CTLA4 and neoplasm: Similar results were observed against breast cancer, for anti-CTLA-4 siRNA-loaded nanoparticles, which significantly reduced CTLA-4-expressing T cells in tumor cells but also in the spleen, leading to tumor regression and increased survival for mice [85].